This has led to a change in the most recent American Heart Association 6 and European Stroke Organization guidelines (presented at the European Stroke Organization Conference 2018, Gothenburg) for the management of acute ischemic stroke. While the overpowering effect of thrombectomy versus standard treatment beyond 6 hours with a number needed to treat of approximately 2 for an improved clinical outcome in both trials is a breakthrough result in acute ischemic stroke therapy, a closer inspection with regard to the time window itself and also to the proposed imaging-based selection process is warranted. Naturally, the total numbers of intravenous thrombolysis (IVT)-treated patients and M2-branch occlusions was negligible in both trials, the former being a significant factor with regard to the large late time window outcome effect.
5

Time Window
DAWN and DEFUSE-3 are not the only trials which included patients in a time window later than 6 hours from symptom onset to groin puncture. REVASCAT in Gothenburg, (publication is pending), whereas results of the late subgroup of ESCAPE were published last year 9 and did not show a heterogeneity of treatment effect between early and late time window patients. In brief, AURORA demonstrated a significant treatment benefit of endovascular therapy versus standard treatment increasing the odds for an improved outcome at day 90 by 2.77 (95% CI, 1.95-3.94; number needed to treat, 2.5), which was a similar result to that published by the Hermes collaboration consisting mostly of within 6 hours patients in 2016. 10 There was no difference in the subgroups defined by age, or Alberta Stroke Program Early CT Scores, however, the treatment effect was stronger from 12 to 24 hours than from 6 to 12 hours. It should be mentioned that these results are not surprising as most of the patients in AURORA come from the DAWN and DEFUSE-3 trials. Also, in this whole setting, it should be noted that another trial (WAKE UP [Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke]) for IVT in wake up patients with diffusionweighted imaging (DWI)/fluid attenuated inversion recovery mismatch within a maximum time of 4.5 hours after wake up was positive. 11 On the one hand, this illustrates that in keeping with the times and actual data we have now, time from symptom onset can no longer serve as the strongest sole emergency treatment criterion (for decision making over whether to deliver IVT and even more so endovascular therapy for acute ischemic stroke). Time, alone, can most definitely not serve as a lone exclusion criterion for reperfusion therapy, at least within the first 24 hours of last seen normal. 3 On the other hand, the idiom "time is brain" should not be abandoned. It remains essential
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that once the patient suspected of an acute stroke syndrome enters the prehospital, hospital, interhospital, and intrahospital pathways and once the diagnosis of acute ischemic stroke is established, the diagnostic workup, the treatment decision making, and the actual treatment itself must be performed as fast as possible. This obligatory triage includes the definition of a neurovascular imaging pathway that guides practitioners on precisely which kind of imaging is necessary in a given patient with given characteristics in a given time window.
Imaging
Besides the time windows, an especially narrow and complex set of imaging inclusion and exclusion criteria varied substantially between the 2 trials. DAWN used a stratification by age and National Institutes of Health Stroke Scale score leading to differing maximum infarct core cutoff volumes measured by a specific imaging software in an automated fashion (>80 years core up to 20 mL, <80 years and National Institutes of Health Stroke Scale 10-19 core up to 30 mL, <80 years and National Institutes of Health Stroke Scale ≥20 core up to 51 mL). DEFUSE-3 allowed a larger core volume (up to 70 mL) but required a perfusion mismatch measured by perfusion computed tomography or magnetic resonance imaging (MRI) of >1.8 (ratio) and 15 mL (penumbra volume), again measured by a specific imaging software in an automated fashion. The median infarct core volume was 8 and 10 mL in DAWN and DEFUSE 3, respectively. More than half of all the trial subjects presented with wake up strokes in both trials. As elaborated by Albers, varying the selection of imaging is a major explanatory factor for varying outcome effect sizes in all the recent trials and especially in the late time window, coining this the "late time window paradox". 5 On the other hand, this imaging-based selection approach for late time window patients using MRI and MRI or computed tomography perfusion imaging techniques places high demands on imaging capabilities and capacities at hospital stroke centers, both in regards to availability and presence of the necessary hardware. On top of this, both trials employed a postprocessing software that is not widely available and comes at an additional cost. It is anticipated that in the near future several vendors will render these services, however, in the interim this impacts negatively broad implementation and generalizability. Ultimately, the definition of what constitutes a stroke alert, the criteria on which it is activated, and the response(s) that it generates will be dependent on the characteristics, expertise, and resources available within a regional stroke system of care. One must also consider that the total number of those patients that receive standard IVT (up to 25% of all acute stroke patients) and early time window endovascular therapy (maximum of 10% with significant overlap to IVT) is probably low. According to recent publications the proportion of potential stroke patients for whom DEFUSE-3 and DAWN criteria apply is ≈2.7%. 12 We, therefore, believe that imaging selection criteria need to be qualified, for example, applying ESCAPE criteria with computed tomography and computed tomography multiphase angiography and volumetry of computed tomographic angiography-based lesion core as a substitute for DWI 13, 14 to the DAWN selection process. Alternatively, the ESCAPE approach could be used out to 12 hours. Given the WAKE UP trial, 11 one could use simple DWI volumetry on a reduced MRI protocol to still fulfill DAWN criteria; however, a reliable vascular imaging modality would still have to be added, for example, high-quality magnetic resonance angiography. This would allow hospitals with interventional capacity as well as those that drip and ship to select patients without the need to implement high-end MRI and perfusion imaging capacities with the required hardware and postprocessing software specifications. Accordingly, further research is needed on the equivalence of more simplified imaging solutions to select patients within the late time window.
Conclusions
For acute stroke patients, the late and the unknown time window of up to 24 hours after last seen normal is now open for treatment with intravenous as well as with endovascular reperfusion therapies. This applies to patients with witnessed onset of symptoms within 6 to 24 hours and wake up stroke, according to secondary analyses to a lesser extend also to unwitnessed stroke, because they have a comparable benefit. The change to a physiological (imaging-based) approach using various, indirectly implied (DWI / clinical mismatch, DWI / fluid attenuated inversion recovery mismatch, collateral status), as well as more directly (perfusion imaging of core and tissue at risk of infarction) shown subtrates of the ischemic penumbra concept has finally entered the stage. The actual time within a prescribed time window alone is not sufficient to determine eligibility for reperfusion therapy in acute ischemic stroke patients. Still, speed to treatment is invaluable.
Treating in the late time window is a major but not the last step into the direction of allowing our stroke patients an access to therapeutic options unheard of fewer than 5 years ago. We concur with Hill and Goyal: identify disabling strokes, image the brain and vessels (quickly) to identify the target patient and then treat fast. 3 Although there is justifiable enthusiasm over DAWN and DEFUSE-3 results, the core principles of acute ischemic stroke management have not changed appreciably: waste no time assembling the requisite focused clinical stroke history and examination, waste no time imaging the brain and blood vessels, waste no time synthesizing the clinical and radiological pictures, waste no time declaratively diagnosing, and waste no time offering definitive fast treatment.
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